New drug promising in CKD
A phase 3 study has shown that finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, can reduce the risk of chronic kidney disease (CKD) progression in patients with type 2 diabetes.
According to manufacturer Bayer, finerenone added to standard therapy reduced the combined risk of time to first occurrence of kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR) ≥40% from baseline over a period of at least four weeks, or renal death. Finerenone also reduced the risk of a composite of time to first occurrence of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or heart failure hospitalisation.
The study, called FIDELIO-DKD, included 5700 patients across 48 countries. Patients were randomised to receive either finerenone 10mg or 20mg orally once daily or placebo added to standard of care, including blood glucose lowering therapies and maximum tolerated doses of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.